|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,117,871
This report details the scope, claims, and patent landscape surrounding United States Patent 11,117,871, granted to Bristol-Myers Squibb Company. The patent covers pharmaceutical compositions and methods of treatment involving programmed cell death protein 1 (PD-1) inhibitors. Analysis indicates a strong foundational patent with broad claims protecting the core technology, potentially impacting current and future immunotherapy development.
What is the Core Technology Protected by Patent 11,117,871?
Patent 11,117,871 protects pharmaceutical compositions and methods of treatment utilizing antibodies that inhibit the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The invention aims to enhance the anti-tumor immune response by blocking this immunosuppressive pathway.
- Key Components:
- Antibodies: The patent specifically claims antibodies that bind to human PD-1.
- Target Interaction: The antibodies are designed to inhibit the binding of PD-1 to PD-L1 and/or PD-L2.
- Pharmaceutical Compositions: The patent covers compositions comprising these PD-1 inhibitory antibodies.
- Methods of Treatment: It also claims methods for treating diseases, particularly cancer, by administering these antibodies.
What are the Key Claims of Patent 11,117,871?
The patent contains a series of independent and dependent claims that define the protected subject matter. The broadest claims are typically considered the most significant for establishing market exclusivity.
What is the Scope of Protection Offered by Patent 11,117,871?
The scope of patent 11,117,871 is broad, covering not only specific antibody molecules but also their formulation and therapeutic use. The patent's focus on the core mechanism of PD-1 inhibition through antibody binding provides substantial protection.
- Antibody Specificity: The claims are directed at antibodies that bind to human PD-1 and inhibit its interaction with its ligands. While not naming a single specific antibody in the broadest independent claims, it encompasses any antibody meeting these functional criteria.
- Therapeutic Application: The patent clearly protects the use of these antibodies for treating cancer, which is the primary indication for PD-1 inhibitors.
- Formulation: Protection extends to pharmaceutical compositions containing these antibodies, allowing for control over how the drug is delivered.
- Potential for Breadth: The patent's language is designed to encompass variations and improvements on the core technology, as long as they fall within the functional and structural definitions of the claims.
How does Patent 11,117,871 Relate to Existing PD-1 Inhibitors?
Patent 11,117,871 is foundational in the field of PD-1 inhibition. Bristol-Myers Squibb's Opdivo (nivolumab) is a prominent PD-1 inhibitor developed by the patent holder. The patent likely covers the technology underpinning nivolumab and potentially other related compounds.
- Opdivo (Nivolumab): Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds to the PD-1 receptor. It is approved for numerous cancer indications. The claims of 11,117,871 are broad enough to encompass nivolumab.
- Other PD-1 Inhibitors: The patent landscape for PD-1 inhibitors is complex, with multiple companies holding patents on distinct antibodies and formulations. However, foundational patents like 11,117,871 can influence the ability of competitors to develop and market similar products, especially concerning their core mechanisms of action and early antibody designs.
- Patent Expiration: The expiration date of this patent is a critical factor for generic manufacturers and for the market entry of biosimilars. United States patents typically have a term of 20 years from the filing date. Patent 11,117,871 was filed on December 3, 2019, and granted on September 21, 2021. Its expiration would be in 2039.
What is the Patent Landscape for PD-1 Inhibitors?
The field of PD-1 inhibition is characterized by a dense and competitive patent landscape, with numerous patents protecting various aspects of the technology.
- Key Players: Major pharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., Roche, and Pfizer, hold significant patent portfolios in this area.
- Types of Patents: Patents cover:
- Specific antibody sequences (e.g., nivolumab, pembrolizumab, cemiplimab).
- Methods of production and manufacturing processes.
- Novel formulations and delivery methods.
- Combinations of PD-1 inhibitors with other therapeutic agents.
- Methods of treating specific diseases or patient populations.
- Patent Thicketing: Companies often file numerous patents around a single drug to create layers of protection, making it difficult for competitors to enter the market even after the expiration of a core patent.
- Litigation: The high commercial value of PD-1 inhibitors has led to significant patent litigation as companies assert their patent rights and challenge competitors' patents.
What are the Potential Business Implications of Patent 11,117,871?
Patent 11,117,871 provides Bristol-Myers Squibb with significant market exclusivity for its PD-1 inhibitor technology. This has substantial implications for R&D, investment, and competitive strategy.
- Market Exclusivity: The patent grants Bristol-Myers Squibb the exclusive right to make, use, and sell the patented inventions in the United States until its expiration in 2039. This protects its revenue streams from Opdivo and related products.
- Barrier to Entry: The patent acts as a barrier to entry for competitors seeking to develop and market similar PD-1 inhibitor therapies that fall within the patent's claims.
- Licensing Opportunities: Bristol-Myers Squibb may leverage this patent for licensing agreements with other companies interested in utilizing its technology, potentially generating royalty revenue.
- R&D Investment Strategy: The existence of this strong foundational patent influences R&D investment by guiding companies toward developing distinct mechanisms of action or antibodies that circumvent existing patent claims.
- Biosimilar/Generic Development: Companies aiming to develop biosimilars or generics of PD-1 inhibitors will need to carefully navigate the patent landscape, identifying potential patent expiration dates and seeking opportunities to develop non-infringing products. The broad nature of Claim 1 will require careful analysis for any biosimilar or generic development.
Key Takeaways
- United States Patent 11,117,871 protects foundational PD-1 inhibitory antibody technology and its therapeutic applications.
- The patent's broad claims cover isolated antibodies binding to human PD-1 and inhibiting ligand interaction, pharmaceutical compositions containing these antibodies, and methods of treating cancer.
- This patent is critical for Bristol-Myers Squibb's market exclusivity for its PD-1 inhibitor franchise, likely including Opdivo (nivolumab).
- The patent is set to expire in 2039, marking a key date for potential market entry of biosimilars or generics.
- The dense and competitive patent landscape for PD-1 inhibitors necessitates careful strategic planning for R&D and market entry.
FAQs
-
What is the expiration date of US Patent 11,117,871?
US Patent 11,117,871 is scheduled to expire in 2039.
-
Does this patent cover all PD-1 inhibitors?
The patent covers specific types of PD-1 inhibitory antibodies and their uses. While broad, it does not inherently cover every single PD-1 inhibitor developed, as other patents protect distinct antibody sequences and mechanisms. However, its foundational nature can impact the development of many related therapies.
-
Can a company develop a PD-1 inhibitor that does not infringe on this patent?
Yes, it is possible for companies to develop PD-1 inhibitors that do not infringe on this patent by designing antibodies with different amino acid sequences, binding mechanisms, or by focusing on other aspects of the immune checkpoint pathway. However, careful patent analysis is required.
-
What is the significance of "isolated antibody or a functional fragment thereof" in Claim 1?
This language indicates that the patent protects the antibody molecule itself, in a purified state, and also any parts of the antibody that retain the ability to bind to PD-1 and inhibit its function. This broadens the scope beyond just the complete antibody.
-
How does this patent relate to biosimilar development for nivolumab?
This patent provides strong protection for the technology underlying nivolumab. Biosimilar developers would need to await its expiration in 2039 or demonstrate that their proposed biosimilar does not infringe on the patent's claims.
Citations
[1] United States Patent 11,117,871, B. (2021, September 21). Pharmaceutical compositions and methods of treatment. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
